AFM-24

N/A

Report date: 2025/08/21 20:00:08

Base Information

Drug NameAFM-24

Drug Alias NameAFM-24

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsLow affinity immunoglobulin gamma Fc region receptor III-A modulators

TargetsLow affinity immunoglobulin gamma Fc region receptor III-AEpidermal growth factor receptor erbB1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPolandGermany +[6]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAffimed

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAffimed Gmbh

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A